Concepedia

Author

J. B. Vermorken

University of Amsterdam

Also Known As

J B Vermorken, J Vermorken, J. B. VERMORKEN, J. B. Vermorken, J. Vermorken, J.B Vermorken, J.B. VERMORKEN, J.B. Vermorken, JB Vermorken, Jan B. Vermorken

141

Publications

4.5K

Citations

32

H-Index

88

Concepts

All Affiliations

University of AmsterdamAntwerp University HospitalVrije Universiteit AmsterdamEuropean Organisation for Research and Treatment of CancerThe Netherlands Cancer Institute
JB

About

J. B. Vermorken is an author at University of Amsterdam specializing in medicine, oncology, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

25

46

2.5K

2

Health Sciences

7

7

315

3

Natural Sciences

1

1

30

4

Public Health

1

1

12

5

Social Sciences

1

1

20

J. B. Vermorken

×

64

Publications

3.8K

Citations

30

H-Index

YearCitations

Impact of Adjuvant Chemotherapy and Surgical Staging in Early-Stage Ovarian Carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm Trial

J. Baptist Trimbos, Ignace Vergote, Giorgio Bolis,

JNCI Journal of the National Cancer Institute

2003

679

Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: A multivariate analysis of 704 patients

E. A. Eisenhauer, J. B. Vermorken, M. van Glabbeke

Annals of Oncology

1997

281

Docetaxel (TaxotereTM) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group

Aarón Sulkes, Joan A. Smyth, C. Sessa,

British Journal of Cancer

1994

220

Advanced epithelial ovarian cancer: 1993 consensus statements

Darlene Allen, J. Baak, D Belpomme,

Annals of Oncology

1993

185

Preclinical in vivo activity of 2',2'-difluorodeoxycytidine (Gemcitabine) against human head and neck cancer.

B.J.M. Braakhuis, Guus A.M.S. van Dongen, J. B. Vermorken,

Data Archiving and Networked Services (DANS)

1991

136

Paclitaxel (TAXOL®) concentrations in brain tumor tissue

J.J. Heimans, J. B. Vermorken, J.G. Wolbers,

Annals of Oncology

1994

130

Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck

Fernando Rivera, Andrzej Kawecki, Sylvie Rottey,

Annals of Oncology

2010

129

Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN): Results of a phase II study

José Trigo, Ricardo Hitt, P. Koralewski,

Journal of Clinical Oncology

2004

108

Comparative pharmacokinetics of cisplatin and three analogues in mice and humans.

Maaike B. van Hennik, W J van der Vijgh, I. Klein,

PubMed

1987

94

Relationship of efficacy with <i>KRAS</i> status (wild type versus mutant) in patients with irinotecan-refractory metastatic colorectal cancer (mCRC), treated with irinotecan (q2w) and escalating doses of cetuximab (q1w): The EVEREST experience (preliminary data)

Sabine Tejpar, Marc Peeters, Yves Humblet,

Journal of Clinical Oncology

2008

92

Page 1